GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » EBITDA Margin %

Biofrontera AG (XTER:B8FK) EBITDA Margin % : 33.56% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biofrontera AG's EBITDA for the three months ended in Dec. 2023 was €2.50 Mil. Biofrontera AG's Revenue for the three months ended in Dec. 2023 was €7.45 Mil. Therefore, Biofrontera AG's EBITDA margin for the quarter that ended in Dec. 2023 was 33.56%.


Biofrontera AG EBITDA Margin % Historical Data

The historical data trend for Biofrontera AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG EBITDA Margin % Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.49 -14.12 148.31 -164.35 -4.10

Biofrontera AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.43 -58.48 6.96 -34.80 33.56

Competitive Comparison of Biofrontera AG's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's EBITDA Margin % falls into.



Biofrontera AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Biofrontera AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-1.321/32.249
=-4.10 %

Biofrontera AG's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=2.5/7.45
=33.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofrontera AG  (XTER:B8FK) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Biofrontera AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG (XTER:B8FK) Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8FK) Headlines

No Headlines